<div>Trial shows tantalising signs that new Alzheimer's drug could benefit early-stage patients</div>
By: Ian Sample Science editor | <div>Trial shows tantalising signs that new Alzheimer's drug could benefit early-stage patients</div> | Neuroscience | The Guardian
Injections of the antibody aducanumab appear to slow condition in patients at earliest stages of disease, raising hopes for treatment
A trial of a new Alzheimer’s drug has shown it could benefit patients in the earliest stages of the disease, raising hopes that a treatment for the devastating condition may finally be on the horizon.
While the trial was designed to assess the safety of the treatment and not whether patients fared better on the drug, an “exploratory analysis” of the data revealed that the treatment appeared to slow the mental decline of patients who responded to the therapy.